SG11202007240QA - Combination of sting agonist and il-15/il15-ra for the treatment of cancer - Google Patents

Combination of sting agonist and il-15/il15-ra for the treatment of cancer

Info

Publication number
SG11202007240QA
SG11202007240QA SG11202007240QA SG11202007240QA SG11202007240QA SG 11202007240Q A SG11202007240Q A SG 11202007240QA SG 11202007240Q A SG11202007240Q A SG 11202007240QA SG 11202007240Q A SG11202007240Q A SG 11202007240QA SG 11202007240Q A SG11202007240Q A SG 11202007240QA
Authority
SG
Singapore
Prior art keywords
cancer
treatment
combination
sting agonist
sting
Prior art date
Application number
SG11202007240QA
Inventor
Nadja Kopp
Justin Leong
Jeffrey Mckenna
Chudi Obioma Ndubaku
Maria Pinzon-Ortiz
Xianhui Rong
Ryan Sullivan
Original Assignee
Novartis Ag
Aduro Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Aduro Biotech Inc filed Critical Novartis Ag
Publication of SG11202007240QA publication Critical patent/SG11202007240QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
SG11202007240QA 2018-02-02 2019-02-01 Combination of sting agonist and il-15/il15-ra for the treatment of cancer SG11202007240QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862625671P 2018-02-02 2018-02-02
PCT/IB2019/050806 WO2019150310A1 (en) 2018-02-02 2019-02-01 Combination of sting agonist and il-15/il15-ra for the treatment of cancer

Publications (1)

Publication Number Publication Date
SG11202007240QA true SG11202007240QA (en) 2020-08-28

Family

ID=65433703

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202007240QA SG11202007240QA (en) 2018-02-02 2019-02-01 Combination of sting agonist and il-15/il15-ra for the treatment of cancer

Country Status (11)

Country Link
US (1) US20220211815A1 (en)
EP (1) EP3746104A1 (en)
JP (1) JP2021512104A (en)
KR (1) KR20200118082A (en)
CN (1) CN111936156A (en)
AU (1) AU2019213843A1 (en)
CA (1) CA3090171A1 (en)
IL (1) IL276363A (en)
RU (1) RU2020128830A (en)
SG (1) SG11202007240QA (en)
WO (1) WO2019150310A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210309692A1 (en) 2018-07-10 2021-10-07 Sperovie Biosciences, Inc. Compounds, compositions, and methods for the treatment of disease
JOP20220174A1 (en) * 2020-02-05 2023-01-30 Novartis Ag Cho cell expressing il-15 heterodimers
CN111592570B (en) * 2020-05-15 2022-04-29 清华大学 Novel STING agonists, methods of preparation and uses thereof
EP4228681A1 (en) * 2020-10-14 2023-08-23 Boehringer Ingelheim International GmbH Combination of a sting agonist and a complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL71691A (en) 1984-04-27 1991-04-15 Yeda Res & Dev Production of interferon-ypsilon
US6174666B1 (en) 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
WO2007001677A2 (en) 2005-05-17 2007-01-04 University Of Connecticut Compositions and methods for immunomodulation in an organism
US8021668B2 (en) 2005-12-12 2011-09-20 Immune Disease Institute, Inc. Integrin alpha L I domain mutants with increased binding affinity
CA2636111C (en) 2006-01-13 2018-04-03 The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health Codon optimized il-15 and il-15r-alpha genes for expression in mammalian cells
DK2769984T3 (en) 2007-05-11 2017-10-16 Altor Bioscience Corp Fusion molecules and IL-15 variants
KR101577849B1 (en) 2008-08-22 2015-12-15 마그나 시팅 인크. Disc recliner with reduced backlash
EP3851459A1 (en) 2010-09-21 2021-07-21 Altor BioScience Corporation Multimeric il-15 soluble fusion molecules and methods of making and using same
LT2996473T (en) 2013-05-18 2019-12-10 Aduro Biotech Inc Compositions and methods for activating "stimulator of interferon gene"-dependent signalling
WO2016018920A1 (en) * 2014-07-29 2016-02-04 Admune Therapeutics Llc Il-15 and il-15ralpha heterodimer dose escalation regimens for treating conditions
CA3033542A1 (en) * 2016-08-30 2018-03-08 Dana-Farber Cancer Institute, Inc. Compositions and uses of biomaterials and activators of innate immunity

Also Published As

Publication number Publication date
CN111936156A (en) 2020-11-13
CA3090171A1 (en) 2019-08-08
KR20200118082A (en) 2020-10-14
AU2019213843A1 (en) 2020-08-20
EP3746104A1 (en) 2020-12-09
US20220211815A1 (en) 2022-07-07
WO2019150310A1 (en) 2019-08-08
IL276363A (en) 2020-09-30
RU2020128830A (en) 2022-03-03
JP2021512104A (en) 2021-05-13

Similar Documents

Publication Publication Date Title
IL272137A (en) Interleukin-21 muteins and methods of treatment
ZA202005934B (en) Il-15 variants and uses thereof
IL272948A (en) Enpp1 inhibitors and their use for the treatment of cancer
IL276363A (en) Combination of sting agonist and il-15/il15-ra for the treatment of cancer
EP3600393A4 (en) Combination therapy for the treatment of solid and hematological cancers
SI3416957T1 (en) 6-heterocyclyl-4-morpholin-4-ylpyridin-2-one compounds useful for the treatment of cancer and diabetes
IL279347A (en) Gremlin-1 antagonist for the prevention and treatment of cancer
GB201820450D0 (en) Compound and its use for the treatment of alpha1-antitryspin deficiency
PT3416945T (en) 6-aryl-4-morpholin-1-ylpyridone compounds useful for the treatment of cancer and diabetes
EP3615056A4 (en) Methods and agents for the detection and treatment of cancer
IL279205A (en) Methods of use of cd24 for the prevention and treatment of leukemia relapse
IL283782A (en) Anellosomes and methods of use
SI3493812T1 (en) Combinations of imetelstat and venetoclax for the treatment of acute myeloid leukaemia
EP3723742C0 (en) Use of fluoroethylnormemantine for the prevention and treatment of anxiety
IL272147A (en) Methods and compositions for the treatment of cancer
IL280262A (en) Compositions and methods for the treatment of cancer
IL270840A (en) Nk-92 cells and il-15 agonist combination therapy
GB201820529D0 (en) Compounds and combinations for the treatment of rosacea
EP3849663C0 (en) Pyrimidinyl-heteroaryloxy-naphthyl compounds and methods of use
GB201820455D0 (en) Compounds and their use for the treatment of alpha1-antitryspin deficiency
GB201820451D0 (en) Compounds and their use for the treatment of alpha1-antitryspin deficiency
GB201815000D0 (en) Treatment of hypothroidism and related conditions
GB201806133D0 (en) Methods and medical uses
AU2017902291A0 (en) Antibody-Drug-Conjugates And Uses Thereof For The Treatment of Cancer